Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Sanwald-Ducray
P
P
Clinical Pharmacology, F Hoffmann-La Roche AG, Basel, Switzerland.
Liogier D'ardhuy
X
X
Jamois
C
C
Banken
L
L